Skip to main content
MyDeficiencies

Betamethasone

Glucocorticoid

Also sold as Celestone, Celestone Soluspan.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Betamethasone is not a drug that lacks depletion-relevant machinery. Its own US prescribing information (Celestone Soluspan, DailyMed) directly states that corticosteroid use causes increased renal excretion of potassium, hypokalemic alkalosis, sodium and fluid retention, and increased calcium excretion, and that concomitant potassium-depleting agents (amphotericin B, diuretics) compound the hypokalemia risk. This runs through renal tubular handling and bone/mineral metabolism rather than through gastrointestinal chelation, gut-flora-dependent synthesis, or betamethasone inducing its own metabolizing enzymes; the label documents betamethasone as the target of CYP3A4-mediated interactions (its metabolism is slowed by ketoconazole and macrolides, sped up by phenytoin, rifampin, carbamazepine and barbiturates), not as an inducer itself.

Glucocorticoid, systemic corticosteroid · ATC H02AB01 · also sold as Celestone Soluspan and Celestone · reviewed 2026-09-23. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Betamethasone in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: ≥2 independent Tier A sources, this drug in the cohort, direct measurement, consistent direction, clinically meaningful magnitude, named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional rather than circulating).
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence to support even yellow, and no circulating claim exists to rebut as white. A disclosed absence of evidence, never reworded as reassurance.

What the research found

Potassium

Orange — Moderate

See study details

Betamethasone causes labeled renal potassium wasting; case reports document symptomatic hypokalemia, including hypokalemic periodic paralysis, specifically after betamethasone injection.

Full detail, limits and 4 references

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional rather than circulating). Orange

Limits on what this shows

  • Key negative/null findings: None found measuring potassium in betamethasone-treated patients and reporting no change; the accessible literature is skewed toward symptomatic case reports, which cannot establish population frequency.
  • At-risk subgroups: Concurrent use of potassium-depleting diuretics or amphotericin B (label-flagged interaction); repeated, supraphysiologic, or non-standard (e.g., illicit/veterinary-formulation) dosing, as reflected in the case-report pattern.
  • Counter-evidence on record: Case reports are Tier B and cannot establish population-level frequency or rule out confounding (e.g., concurrent diuretic use, pre-existing channelopathy in the familial-paralysis case). No Tier A dose-response study was located.

Regulatory status

US label (Celestone Soluspan) lists "increased excretion of potassium," "hypokalemic alkalosis," and "potassium loss" as documented effects/adverse reactions; recommends dietary potassium supplementation may be necessary.

Population evidence

Four published case reports of betamethasone-induced hypokalemia/hypokalemic periodic paralysis: an intramuscular-injection case (2024, PMID 38770411), a pregnancy case (2011, PMID 21252779), a pregnancy hypokalemic paraplegia case (2014, PMID 25121034), and simultaneous familial cases following illicit betamethasone injection (2025, PMID 39952820). No controlled cohort quantifying incidence or magnitude of hypokalemia across routine therapeutic dosing was found.

Mechanism

Named: corticosteroid mineralocorticoid-like activity on the distal renal tubule increases potassium secretion/excretion (label-stated).

Counter-evidence held on record

Bounded to a real but not universally quantified renal-wasting effect; do not present as guaranteed or dose-independent. No potassium supplement dose is recommended by this dossier — any repletion decision belongs with a prescriber monitoring serum potassium.

Sodium

Orange — Moderate

See study details

Average-to-large betamethasone doses cause dose-dependent sodium and fluid retention; this is a retention risk running opposite to "depletion," and supplementation would be the hazard, not the remedy.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional rather than circulating). Orange

Limits on what this shows

  • Key negative/null findings: Betamethasone is repeatedly described (secondary reference) as having comparatively low/minimal mineralocorticoid activity relative to older corticosteroids, with the retention effect emerging mainly "with high doses" — i.e., not a uniform low-dose effect.
  • At-risk subgroups: Label specifically cautions use in congestive heart failure, hypertension, or renal insufficiency because of sodium retention and potassium loss risk.
  • Counter-evidence on record: No source found disputing the retention direction; the main caveat is dose-dependence (low at typical doses, more pronounced at high/repeated doses), which is recorded as a bound, not a contradiction.

Regulatory status

US label: "average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention"; adverse reactions list "sodium retention" and "fluid retention." A secondary consumer drug reference mirrors the label and adds that betamethasone has "minimal sodium retention activity; however, may increase with high doses."

Population evidence

Label-level pharmacovigilance/class labeling; no betamethasone-specific quantified trial of sodium retention magnitude was located in this review.

Mechanism

Named: residual mineralocorticoid receptor activity of betamethasone promoting distal tubular sodium reabsorption, dose-dependent.

Counter-evidence held on record

This is an excess/retention risk, not a dietary sodium deficiency. Never frame this finding as a reason to increase sodium intake; the clinical concern runs toward restriction and monitoring for edema, hypertension, and heart failure, especially in patients with renal or cardiac impairment.

Calcium

Orange — Moderate

See study details

Betamethasone increases urinary calcium excretion (label) and interferes with intestinal calcium absorption in drug-specific animal studies; human data are class-level, not betamethasone-stratified.

Full detail, limits and 8 references

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional rather than circulating). Orange

Limits on what this shows

  • Key negative/null findings: No study found reporting betamethasone leaves calcium absorption or excretion unchanged; all located betamethasone-specific data point the same direction (reduced absorption / increased excretion).
  • At-risk subgroups: Repeated or prolonged systemic courses (standard glucocorticoid-induced osteoporosis risk window); pre-existing low dietary calcium or vitamin D status, per the animal dose-diet interaction data.
  • Counter-evidence on record: Confounding by indication is a live concern for any human bone-density association (underlying inflammatory disease itself affects bone turnover); per Hard Rule 2, fracture or low BMD alone is a clinical outcome, not calcium deficiency, and is not graded here as a nutrient finding. The animal calcium-absorption data are the direct, drug-specific evidence; the human osteoporosis literature is cited as class-level context only.

Regulatory status

US label states plainly: "all corticosteroids increase calcium excretion," under Cardio-renal Warnings, alongside notes that corticosteroids "increase bone resorption" and may cause osteoporosis.

Population evidence

Betamethasone-specific animal (chick) studies by Blahos, Care, Fox and colleagues (1978 PMID 702018; 1983 PMID 6654320 and PMID 6688057; 1986 PMID 3439529; 1989 PMID 2591879) repeatedly show betamethasone reduces duodenal/intestinal calcium absorption efficiency, compounded by low-calcium diets. A pig study (Maunder et al. 1986, PMID 3754194) found betamethasone altered plasma and intestinal calcium-binding protein alongside 25-hydroxyvitamin D3 metabolism. No human, betamethasone-specific study measuring serum or urinary calcium was located; human support is class-level glucocorticoid-induced-osteoporosis literature (Compston 2018, PMID 29691807; Hu & Adachi 2019, PMID 31094232) that does not stratify to betamethasone by name.

Mechanism

Named: increased renal calcium excretion (label) plus reduced intestinal calcium absorption via interference with vitamin D-dependent transport (drug-specific animal data).

Counter-evidence held on record

State the boundary explicitly: this is functional/urinary calcium loss and reduced absorption efficiency in animal models, not a confirmed human serum-calcium deficit specific to betamethasone. Low bone mineral density or fracture is a clinical outcome and must not be relabeled as "calcium deficiency."

Vitamin D

Yellow — Low

See study details

Drug-specific animal studies show betamethasone alters vitamin D metabolite handling alongside reduced intestinal calcium absorption; no human data specific to betamethasone were found.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: None found specifically contradicting the animal-model direction; the gap is entirely on the human-data side, not a contradicting finding.
  • At-risk subgroups: Not established in humans; by extrapolation from the animal mechanism, patients with pre-existing low vitamin D status on repeated systemic courses would be the plausible at-risk group, but this is not confirmed by direct data.
  • Counter-evidence on record: Species difference (chick, pig) limits direct human extrapolation; no dose-response or human confirmatory study found despite a genuine search.

Regulatory status

Not addressed in the label.

Population evidence

Blahos, Care & Sommerville (1983, PMID 6688057): chick model, betamethasone reduced duodenal calcium absorption and 1,25-dihydroxyvitamin D3 production in the same experiment. Maunder et al. (1986, PMID 3754194): pig model, betamethasone affected plasma/intestinal calcium-binding protein and 25-hydroxyvitamin D3 metabolism. Both are Tier B, animal, betamethasone-specific. No human betamethasone-specific vitamin D study was located.

Mechanism

Named (animal data): glucocorticoid interference with renal 1-alpha-hydroxylase-dependent conversion of vitamin D to its active metabolite and with vitamin D-dependent calcium-binding protein expression.

Counter-evidence held on record

Mechanistic plausibility only, from animal data. No human confirmatory study exists for betamethasone specifically; do not present as an established human deficiency, and no supplement dose is recommended.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

A betamethasone-specific animal study titled "Effect of betamethasone on mitochondrial oxidative phosphorylation in ischemic canine myocardium" exists in the literature (PMID 7382546); its abstract could not be retrieved this session, so direction and magnitude are disclosed as unconfirmed rather than asserted.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: None retrievable; abstract inaccessible.
  • At-risk subgroups: Not determinable from available data.
  • Counter-evidence on record: None retrievable this session. This entry should be revisited in a future review once the abstract can be accessed.

Regulatory status

Not addressed in the label.

Population evidence

Sunamori M, Harrison CE Jr, 1980, PMID 7382546. Title and bibliographic metadata (journal, year, authors) were confirmed via a PubMed search listing; the abstract page returned a bot-verification challenge on repeated attempts and could not be read this session. A related paper by the same first author, "Protective effect of betamethasone on the subendocardial ischemia after the cardiopulmonary bypass" (1978, PMID 659503), suggests this author's line of work in this area concerned protective/attenuating effects of betamethasone on ischemic myocardium, but this is a title-level inference, not a confirmed finding, and is not used to assign a direction here.

Mechanism

Plausible by title alone: the study directly targets mitochondrial oxidative phosphorylation, the correct mechanism class for this category. No further mechanistic detail could be confirmed.

Counter-evidence held on record

Direction and magnitude are unconfirmed. Do not present as evidence of either mitochondrial harm or mitochondrial benefit; this entry records that a directly relevant, drug-specific study exists and flags an access gap for follow-up, not a graded effect.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Orange — Moderate

See study details

A single human study found transient suppression of the antioxidant enzyme glutathione peroxidase-3 and a 69-96% rise in a lipid oxidative-damage marker for up to 72 hours after antenatal betamethasone; drug-specific animal data in other tissues show the opposite, protective direction.

Full detail, limits and 3 references

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional rather than circulating). Orange

Limits on what this shows

  • Key negative/null findings: Betamethasone-specific animal data point the opposite direction in other tissues and contexts: it attenuated oxidant stress in endothelial cells from fetal lambs with persistent pulmonary hypertension (Chandrasekar, Eis, Konduri 2008, PMID 18043518, title/abstract-snippet level), and repetitive prenatal glucocorticoid therapy (betamethasone) increased copper-zinc superoxide dismutase activity and reduced oxidative stress in preterm lamb lungs (Walther, Jobe, Ikegami 1998, PMID 9655786). This is recorded as genuine conflicting evidence, not reconciled by this review.
  • At-risk subgroups: Preterm neonates exposed to antenatal betamethasone within the 24-72 hour window before/after birth, per the human study population.
  • Counter-evidence on record: Effect is explicitly described as transient in the source study. Directionality is tissue- and context-dependent: lung and vascular endothelial tissue in animal models show antioxidant enzyme upregulation and reduced oxidative markers, while the human study measured systemic (plasma) markers in newborns. No active-comparator or dose-response data were found.

Regulatory status

Not addressed in the label; this is a literature-only finding.

Population evidence

Verhaeghe J, van Bree R, Van Herck E (2009, PMID 19926412): prospective single-center cohort, 105 newborns <34 weeks gestational age. Glutathione peroxidase-3 (GPx3) concentrations were suppressed within 24 hours of betamethasone exposure before birth; malondialdehyde (MDA), a lipid oxidative-damage marker, "remained elevated by 69-96% for at least 72 h after the last betamethasone." GPx3 and MDA were negatively correlated (r=-0.38, p<0.001).

Mechanism

Named: acute glucocorticoid-mediated downregulation of the GPx3 antioxidant defense system, permitting a longer-lasting but transient rise in lipid oxidative damage.

Counter-evidence held on record

Do not present as a uniform "betamethasone causes oxidative stress" claim. The only human data are from a bounded perinatal exposure window and a transient marker rise; drug-specific animal data in lung and vascular tissue show antioxidant enzyme induction instead. No antioxidant supplement dose is recommended.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

See study details

A betamethasone-specific animal study found increased copper-zinc superoxide dismutase activity in lung tissue after repeated dosing, an adaptive/protective signal rather than a depletion; a separate topical-steroid rabbit study referencing aqueous-humor copper could not be verified this session.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: No betamethasone-specific study was found showing reduced serum or tissue copper; the one quantified finding located runs in the increase direction.
  • At-risk subgroups: Not established; the source population is preterm lambs receiving repetitive antenatal dosing.
  • Counter-evidence on record: Single animal study, snippet-level detail only (full abstract not retrieved); route (systemic/antenatal) differs from the inaccessible topical-steroid rabbit study, limiting comparability.

Regulatory status

Not addressed in the label.

Population evidence

Walther, Jobe, Ikegami (1998, PMID 9655786): preterm lamb model; repetitive prenatal betamethasone increased copper-zinc superoxide dismutase (Cu/Zn-SOD) activity "after 2 doses," per the search-listing snippet, alongside reduced lung oxidative stress. A separate title, "Relationship between the concentration of copper and iron in the aqueous humour and intraocular pressure in rabbits treated with topical steroids" (Iqbal et al. 2002, PMID 11885791), references betamethasone among topical steroids tested, but its abstract could not be retrieved this session (page returned no extractable content on repeated attempts) and is not used to support a direction here.

Mechanism

Named (Cu/Zn-SOD finding): glucocorticoid-induced upregulation of a copper-dependent antioxidant enzyme, an adaptive response rather than a copper-wasting mechanism.

Counter-evidence held on record

This is a reverse-direction (adaptive/increase), not a depletion, finding. Do not present as a reason for copper supplementation; the available direction, if anything, argues against a depletion narrative for this pathway.

Iron

Yellow — Low

See study details

A dexamethasone-specific rat study found repeated glucocorticoid dosing reduces hepatic transferrin receptor 1 protein and liver iron concentration; no betamethasone-specific iron-status data exist despite a full re-search of this category with unrestricted tool access.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: None located for betamethasone, and none for dexamethasone either; this is the only hepatic-iron study found for any glucocorticoid-class member, so there is no contradicting result on record, only an absence of independent replication.
  • At-risk subgroups: Not established for betamethasone. By class extrapolation, prolonged or repeated systemic dosing (the rat model used 21 consecutive days) is the plausible risk window; a brief antenatal betamethasone course is a materially different exposure pattern.
  • Counter-evidence on record: Species (rat, not human) and molecule (dexamethasone, not betamethasone) both limit direct extrapolation; dexamethasone and betamethasone are pharmacologically similar potent, long-acting glucocorticoids, the same class-extrapolation logic already used for Gut microbiome risk in this dossier, but they are not identical molecules and no betamethasone-specific confirmatory study exists. A separate, unrelated topical-steroid rabbit study referencing aqueous-humor iron and copper (Iqbal et al. 2002, PMID 11885791, also cited under Copper) remains inaccessible this session and is not used to support this entry.

Regulatory status

Not addressed in the label.

Population evidence

Li H, Jiang S, Yang C, Yang S, He B, Ma W, Zhao R (2017, Nutrients 9(6):617, DOI 10.3390/nu9060617; erratum PMID 29642600 corrects an author-affiliation typo only, not the findings): Sprague-Dawley rats, n=30 (15 per group), dexamethasone 0.1 mg/kg/day intraperitoneally for 21 days versus vehicle. Hepatic TFR1 protein expression was significantly reduced (p=0.03) and liver iron concentration was significantly reduced (p=0.02) in the dexamethasone group, confirmed by Prussian blue staining showing reduced hepatic iron density; TFR1 mRNA was unchanged, indicating post-translational regulation. This is Tier C for betamethasone: dexamethasone, not betamethasone, was the drug studied, and betamethasone is not mentioned anywhere in the paper. No betamethasone-specific study of serum iron, ferritin, transferrin, hepcidin, or hepatic iron was located this session despite multiple phrasings ("betamethasone iron," "betamethasone ferritin," "betamethasone transferrin," "betamethasone hepcidin," "glucocorticoid DMT1 ferroportin betamethasone") run against PubMed search-listing pages, Crossref, Europe PMC, and Semantic Scholar.

Mechanism

Named (dexamethasone data only): suppressed STAT5 transcriptional activity combined with enhanced iron-regulatory-protein/iron-responsive-element (IRP-IRE) binding, producing post-translational downregulation of hepatic TFR1 and reduced hepatic iron uptake/storage. No mechanism has been demonstrated for betamethasone specifically.

Counter-evidence held on record

Class extrapolation only, from a single dexamethasone rat study; no betamethasone-specific human or animal iron data exist at any tier. Do not present as an established betamethasone-iron-depletion claim, and no iron supplement dose is recommended.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

Dexamethasone, a closely related synthetic glucocorticoid, disrupts gut microbiota composition in drug-specific studies; a direct betamethasone mouse study instead found pre-existing microbiota composition predicted drug response, not that betamethasone itself reshaped the microbiome.

Full detail, limits and 3 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: The one betamethasone-specific study located is non-supportive of direct microbiome disruption by the drug: it shows baseline microbiota predicting treatment response, the reverse causal direction from a "betamethasone disrupts the microbiome" claim. This is recorded explicitly as a null/non-supportive finding for direct causation.
  • At-risk subgroups: Not established for betamethasone specifically.
  • Counter-evidence on record: Class extrapolation limitation: dexamethasone and betamethasone are pharmacologically similar (both potent, long-acting glucocorticoids) but are not identical molecules, and this review found no betamethasone-specific evidence of the drug causing dysbiosis.

Regulatory status

Not addressed in the label.

Population evidence

Class-level (Tier C, betamethasone not in cohort): dexamethasone-specific probiotic/immunosuppression gut-microbiota study (Li Y et al. 2021, PMID 34328088) and a glucocorticoid-class dysbiosis/glycolipid metabolism study (Zhang Q et al. 2024, PMID 38226811, drug not confirmed by name in the listing snippet). Betamethasone-specific (Tier B, this drug in cohort): Debes KP et al. (2020, PMID 31744592), Swiss Webster mice with oxazolone-induced atopic dermatitis and fecal microbiota transplantation; gut microbiota composition correlated strongly with disease severity, and betamethasone normalized clinical response across high- and low-responding microbiota recipients, but the abstract does not describe betamethasone altering microbiota composition itself.

Mechanism

Plausible by class: systemic glucocorticoid immunomodulation altering gut immune-microbe interactions, demonstrated for dexamethasone; not directly demonstrated for betamethasone.

Counter-evidence held on record

Class extrapolation, not drug-specific confirmation. The only direct betamethasone data available argue against, rather than for, the drug itself reshaping gut microbiota.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

See study details

The same 1980 betamethasone-specific study on myocardial oxidative phosphorylation directly concerns ATP-generating capacity; its findings could not be confirmed this session, so this entry, like mitochondrial burden, records an open question rather than a direction.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: None retrievable; abstract inaccessible.
  • At-risk subgroups: Not determinable from available data.
  • Counter-evidence on record: None retrievable this session.

Regulatory status

Not addressed in the label.

Population evidence

Sunamori M, Harrison CE Jr, 1980, PMID 7382546 (see Mitochondrial burden entry and Overlap map; this is the same underlying source, cited here because oxidative phosphorylation is the direct biochemical process of mitochondrial ATP synthesis). No other betamethasone-specific ATP-production study was located despite a dedicated search.

Mechanism

Plausible by title alone: oxidative phosphorylation is the ATP-generating process; direction and magnitude not confirmed.

Counter-evidence held on record

Do not present as evidence of impaired ATP production; the source's direction and magnitude are unconfirmed. See the Overlap map: this entry and Mitochondrial burden share the same single source and must not be read as two independent confirmations.

Oxygen delivery / utilization

Yellow — Low

See study details

A betamethasone-specific fetal-sheep study found erythrocyte and leukocyte counts increased after 48-hour betamethasone infusion; this is an increase, not a depletion, in oxygen-carrying red-cell parameters, and no betamethasone-specific human hemoglobin/hematocrit study was located.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also used for context flags and reverse-direction (protective) findings. Yellow

Limits on what this shows

  • Key negative/null findings: None found measuring hemoglobin, hematocrit, or oxygen-carrying capacity in betamethasone-treated subjects and reporting no change; this is the only quantified betamethasone-specific hematologic measurement located this session.
  • At-risk subgroups: Fetal/perinatal exposure window, per the source population; not established for non-perinatal human systemic dosing.
  • Counter-evidence on record: Single animal study; species is sheep, and exposure is a continuous 48-hour intravenous infusion rather than the intermittent intramuscular dosing used clinically, which may not translate directly to the human fetal or maternal red-cell response to a standard antenatal course. No human betamethasone-specific hemoglobin, hematocrit, or tissue-oxygenation study was located despite a full re-search across PubMed search-listing pages, Crossref, Europe PMC, and Semantic Scholar with multiple phrasings.

Regulatory status

Not addressed in the label.

Population evidence

Anwar MA, Schwab M, Poston L, Nathanielsz PW (1999, Am J Physiol Heart Circ Physiol 276(4):H1137-H1143, PMID 10199835, DOI 10.1152/ajpheart.1999.276.4.H1137): fetal sheep at 128 days gestation given intravenous betamethasone for 48 hours at doses producing fetal plasma betamethasone concentrations comparable to human maternal antenatal dosing for fetal lung maturation, versus vehicle-infused controls. Quoting the abstract directly: "erythrocyte and leukocyte counts were increased in betamethasone-infused fetuses." The same experiment also found enhanced femoral small-artery sensitivity to depolarizing potassium and to acetylcholine, and decreased response to bradykinin and forskolin, with the authors concluding that "multiple mechanisms operate to increase fetal vascular resistance during antenatal betamethasone exposure," of which the erythrocyte/leukocyte rise is one.

Mechanism

Named by the source only as one of several contributors to raised fetal vascular resistance; not further mechanistically dissected in this paper. Independently, glucocorticoids as a class are established stimulators of erythropoiesis (glucocorticoid receptor synergy with HIF-1alpha and PPAR-alpha promoting BFU-E progenitor self-renewal, and potentiation of the erythropoietin response), a Tier C, class-level mechanism cited here only as corroborating context, not as betamethasone-specific evidence.

Counter-evidence held on record

This is a reverse-direction (increase), not a depletion, finding, consistent with the general pharmacology of glucocorticoids stimulating erythropoiesis. Do not present as a red-cell or oxygen-delivery deficiency and do not use to suggest anemia risk; no supplement or clinical action is recommended from this single animal finding.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Zinc

    Where it comes from: Generic "corticosteroids deplete zinc" framing common in supplement-marketing and drug-mugging-style consumer content, extended across the corticosteroid class; this review could not trace the claim to a specific live source for betamethasone this session (web-search quota exhausted; several targeted consumer-health URLs returned 404 or resolved to unrelated homepage content).

    Why it fails: A dedicated PubMed search ("betamethasone zinc," 45 results) found only drug-delivery formulation studies using zinc as an excipient or nanoparticle carrier for betamethasone (e.g., zinc-doped mesoporous silica microneedle patches, PLGA/PLA nanoparticle release profiles) — not physiological zinc depletion. No Tier B or Tier C mechanism or data of any kind was found linking betamethasone, or glucocorticoids generally, to zinc status.

  • Magnesium

    Where it comes from: Generic "corticosteroids deplete magnesium" framing, similarly extended across the class in consumer content; specific live source could not be traced this session for the same reasons as above.

    Why it fails: A dedicated PubMed search ("betamethasone magnesium") found only studies co-administering magnesium sulfate, a distinct tocolytic drug, alongside betamethasone in preterm-labor protocols (e.g., neuroinflammation and preterm-labor drug-candidate co-administration studies) — not betamethasone affecting magnesium status. No supporting mechanism or data was found.

All references used above
  1. CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injection, suspension — prescribing information, Organon LLC. — DailyMed SPL, setid bf78d1be-42d7-4837-92a5-49113a79278f. Regulatory label, Tier A.
  2. RxList. Betamethasone generic drug monograph. — Consumer/pharmacist reference mirroring label electrolyte content, with added note on dose-dependent sodium retention. Tier D (consumer reference), used only to corroborate label-derived facts, not as independent evidence.
  3. Drugs.com. Betamethasone food interactions. — Consumer reference noting potassium supplementation advisory. Tier D.
  4. Ebrahimi P, Taheri H, Mousavinejad SA, Nazari P. Hypokalemic paralysis following intramuscular betamethasone injection: A case report and review of literature. Clin Case Rep. 2024. — Case report, betamethasone in cohort. Tier B.
  5. Teagarden CM, Picardo CW. Betamethasone-induced hypokalemic periodic paralysis in pregnancy. Obstet Gynecol. 2011. — Case report, betamethasone in cohort. Tier B.
  6. Kulkarni M, Tv S, Gopal N. Hypokalemic paraplegia in pregnancy. J Clin Diagn Res. 2014. — Case report, betamethasone in cohort. Tier B.
  7. Chen B, Counts CJ, Maresca P, Greller HA, Heller MJ. Simultaneous Cases of Familial Hypokalemic Periodic Paralysis Induced by Illicit Injection of Betamethasone. J Emerg Med. 2025. — Case report, betamethasone in cohort. Tier B.
  8. Fox J, Care AD, Blahos J. Effects of low calcium and low phosphorus diets on the duodenal absorption of calcium in betamethasone-treated chicks. 1978. — Animal study, betamethasone in cohort. Tier B; abstract accessed via search-listing title only.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  9. Blahos J, Care AD, Sommerville BA. The effect of betamethasone on duodenal calcium absorption and 1,25-dihydroxy vitamin D3 production in the chick. 1983. — Animal study, betamethasone in cohort. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  10. Blahos J, Care AD, Fox J. The effects of betamethasone, low calcium and low phosphorus diets on growth in chicks. 1983. — Animal study, betamethasone in cohort. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  11. Blahos J, Care AD, Fox J. Effect of betamethasone and calcium and phosphorus deficient diets on the intestinal absorption of calcium and phosphate. 1986. — Animal study, betamethasone in cohort. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  12. Blahos J, Care AD, Abbas SK. Comparison of effects of verapamil, low calcium diet and betamethasone on duodenal calcium absorption efficiency in the chick. 1989. — Animal study, betamethasone in cohort. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  13. Maunder EM, et al. The effects of betamethasone on plasma and intestinal calcium binding protein and on 25-hydroxyvitamin D3 metabolism in the pig. 1986. — Animal study, betamethasone in cohort. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  14. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018. — Narrative review, class-level (glucocorticoids generally). Tier C for betamethasone — this drug not confirmed in a specific studied cohort.Class-level source; betamethasone not stratified. Tier C only.
  15. Hu K, Adachi JD. Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab. 2019. — Narrative review, class-level. Tier C for betamethasone.Class-level source; betamethasone not stratified. Tier C only.
  16. Verhaeghe J, van Bree R, Van Herck E. Oxidative stress after antenatal betamethasone: acute downregulation of glutathione peroxidase-3. 2009. — Prospective cohort, n=105 newborns <34 weeks gestation, betamethasone in cohort, direct measurement. Tier A.
  17. Chandrasekar I, Eis A, Konduri GG. Betamethasone attenuates oxidant stress in endothelial cells from fetal lambs with persistent pulmonary hypertension. 2008. — Animal study, betamethasone in cohort. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  18. Walther FJ, Jobe AH, Ikegami M. Repetitive prenatal glucocorticoid therapy reduces oxidative stress in the lungs of preterm lambs. 1998. — Animal study, betamethasone in cohort (per search-listing snippet: "copper-zinc superoxide dismutase activity increased after 2 doses" of betamethasone). Tier B.Full abstract not retrieved this session; snippet-level detail only via PubMed search listing.
  19. Sunamori M, Harrison CE Jr. Effect of betamethasone on mitochondrial oxidative phosphorylation in ischemic canine myocardium. 1980. — Animal study, betamethasone in cohort (by title). Tier B, direction unconfirmed.Blocked: PubMed abstract page returned a bot-verification (reCAPTCHA) challenge on two attempts; abstract not retrieved. Title/metadata only.
  20. Sunamori M. Protective effect of betamethasone on the subendocardial ischemia after the cardiopulmonary bypass. 1978. — Animal/clinical study, betamethasone in cohort (by title). Tier B, direction unconfirmed; cited only as context for the 1980 study above, not as independent supporting evidence.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  21. Iqbal Z, Muhammad Z, Shah MT, Bashir S, Khan T, Khan MD. Relationship between the concentration of copper and iron in the aqueous humour and intraocular pressure in rabbits treated with topical steroids. 2002. — Animal study, topical steroids including betamethasone (by title, route differs from systemic/injectable use). Tier B, not used to assign a grade.Blocked: abstract page returned no extractable content on two attempts. Title/metadata only; not used as supporting grading evidence.
  22. Debes KP, Evdina NA, Laigaard A, Larsen JM, Zachariassen LF, Hansen CHF, Hansen AK. Betamethasone Treatment for Atopic Dermatitis in Gut Microbiota Transplanted Mice. 2020. — Animal study, betamethasone in cohort, direct measurement of microbiota-treatment interaction. Tier B; non-supportive of direct betamethasone-induced dysbiosis.
  23. Li Y, et al. Probiotic intervention study in dexamethasone-induced immunosuppression. Biomed Pharmacother. 2021. — Dexamethasone in cohort, betamethasone not studied. Tier C for betamethasone.Class member (dexamethasone) studied, not betamethasone. Tier C only; title/metadata confirmed via PubMed search listing.
  24. Zhang Q, et al. Gut microbiota dysbiosis and decreased levels of acetic and propionic acid participate in glucocorticoid-induced glycolipid metabolism disorder. mBio. 2024. — Glucocorticoid-class study; specific drug not confirmed in available listing snippet. Tier C for betamethasone.Specific drug(s) studied not confirmed from available metadata; treated as class-level, Tier C, pending confirmation.
  25. Yates CR, Chang C, Kearbey JD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. 2003. — Mechanistic pharmacology study; betamethasone referenced by title. Tier B.Full abstract not retrieved this session; title/metadata confirmed via PubMed search listing.
  26. Anwar MA, Schwab M, Poston L, Nathanielsz PW. Betamethasone-mediated vascular dysfunction and changes in hematological profile in the ovine fetus. Am J Physiol Heart Circ Physiol. 1999;276(4):H1137-H1143. — Animal study, betamethasone in cohort, direct measurement of erythrocyte and leukocyte counts. Tier B. Full abstract retrieved verbatim via the Crossref API on re-research (journals.physiology.org and pubmed.ncbi.nlm.nih.gov both blocked this citation directly this session; see access-note).
  27. Li H, Jiang S, Yang C, Yang S, He B, Ma W, Zhao R. Long-Term Dexamethasone Exposure Down-Regulates Hepatic TFR1 and Reduces Liver Iron Concentration in Rats. Nutrients. 2017;9(6):617. — Animal study, dexamethasone in cohort, betamethasone not studied. Tier C for betamethasone. Full abstract retrieved via the publisher (MDPI) page on re-research.Class member (dexamethasone) studied, not betamethasone. Tier C only.
  28. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: H02AB01 betamethasone. — Regulatory classification reference confirming ATC code, class (glucocorticoids), and defined daily doses for oral and parenteral betamethasone.